Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
A modest gift card significantly increased enrollment of low-income individuals in a patient registry designed to accelerate Alzheimer’s disease clinical trials. Targeted outreach may be more cost-effective than offering larger prizes.
Researchers at St. Jude Children's Research Hospital found that midkine protein prevents Alzheimer's disease by blocking amyloid beta assembly growth. Midkine inhibits amyloid beta elongation and secondary nucleation, two specific phases during assembly formation.
The Fork It Fund has awarded $1 million to support a major initiative at Stevens INI, accelerating scientific discovery by making critical research data more accessible worldwide. GAAIN is a global data-sharing platform connecting Alzheimer's disease and dementia-related data repositories from around the world.
A recent study published in Alzheimer's & Dementia found that women with Alzheimer's disease have a notable loss of unsaturated fats, such as omega-3 fatty acids, in their blood compared to healthy women. This suggests that lipids containing omega-3 fatty acids may play a crucial role in the risk for Alzheimer's between the sexes.
Dr. David Rubinsztein shares his personal journey from childhood curiosity to discovering autophagy, a natural process that clears toxic proteins causing devastating neurodegenerative diseases. His research has established autophagy upregulation as a viable therapeutic strategy for conditions affecting millions worldwide.
Early-life changes in fAD brain cells have been identified using stem cell-derived brain organoids, revealing key features of Alzheimer's disease. Treatment with Thymosin beta 4 has shown promise in reversing AD-specific changes.
Research at DZNE suggests that immune response plays a significant role in Alzheimer's disease, causing olfactory dysfunctions by attacking neuronal fibers. This may enable the development of early diagnosis and treatment methods.
Researchers from FAU and the Sensing Institute created a detailed computer model of the mouse brain's vasculature, simulating how brain blood vessels respond to hemodynamics and vasodynamics. The model shows that transitional vessels play a critical role in regulating flow and protecting the brain during increased activity.
A recent UC Irvine study reveals that women with Down syndrome exhibit advanced signs of Alzheimer's disease at the same average age of diagnosis as men. The research highlights the need for sex-specific approaches in treating Alzheimer's, particularly in clinical trials.
Researchers have established a causal link between mitochondrial dysfunction and cognitive symptoms associated with neurodegenerative diseases. By stimulating mitochondrial activity, they observed an improvement in memory deficit symptoms in animal models. The study opens the door to considering mitochondria as a new therapeutic target.
Researchers have discovered a new approach for treating proteinopathies by targeting dysregulated nuclear speckles, which can lead to neuron degeneration. Pyrvinium pamoate has been shown to improve proteostasis in various disease models, including Alzheimer's, Parkinson's, and tauopathies.
Alzheimer's disease is a mounting crisis in China, affecting nearly one-fourth of the global total. New diagnostic techniques, treatments, and public health initiatives are being implemented to address the growing burden.
Researchers share updates on Alzheimer's disease research, focusing on early stages of the disease for preventive therapies. Current treatments, such as antibody treatments, slow the course but don't stop the disease, and have serious side effects.
SuperAgers, individuals with exceptional memory performance beyond their age, have been studied for 25 years. Their brains show a distinct neurobiological profile, linked to resistance and resilience mechanisms that may prevent Alzheimer's disease progression.
Researchers at Harvard Medical School found that lithium loss in the brain is an early change leading to Alzheimer's, while a novel lithium compound can reverse memory in mice. The study suggests a new theory of the disease and a potential strategy for diagnosis and treatment.
Researchers found that patients with Alzheimer's disease have reduced ability to absorb cholesterol from the cerebrospinal fluid, and this impairment is linked to the presence of the APOE4 variant. The study suggests that efficient delivery of cholesterol to neurons is essential for their function and maintenance.
A team of UC Irvine researchers has identified a promising nonpharmaceutical treatment that can restore energy levels in aging brain cells, improving their ability to clear damaging amyloid protein aggregates. The treatment, which combines nicotinamide and epigallocatechin gallate, was found to reverse age-related cellular deficits and...
Researchers at Brown University have identified a brain-based biomarker that can predict mild cognitive impairment development into Alzheimer's disease. They used a custom-built tool to analyze electrical activity from neurons and found distinct differences in beta events between patients who developed the disease and those who did not.
A technology expert predicts AI-based medicine will revolutionise care for Alzheimer’s and diabetes, but access must be made available to all patients. The author highlights key innovations such as diagnostic imaging and surgical robots that will aid in more accurate diagnoses and treatments.
Researchers discovered that magnetized surfaces significantly influence amyloid protein assembly, forming more fibrils and longer structures when aligned in one direction. The study suggests a new physical factor, Chiral-Induced Spin Selectivity (CISS), plays a direct role in protein self-assembly.
A new study by Stanford researchers reveals that declining proteostasis in the brain leads to increased protein aggregation, which is linked to neurodegenerative diseases. The findings were made using the turquoise killifish model, and shed light on the fundamental molecular principles of aging.
A study led by Dr. Jessica Bernard at Texas A&M University investigates the role of the cerebellum in cognitive functions such as memory and language, with the aim of developing a non-invasive therapeutic approach using Theta burst simulation (TBS) to improve outcomes for older adults.
The FDA has authorized artificial intelligence devices for Alzheimer's and related dementias despite limited demographic data. Disease status, age, sex, and race were reported for fewer than half of devices, raising concerns about real-world generalizability.
Researchers aim to uncover how menopause and lifestyle factors shape brain aging in women during midlife. The three-year project will analyze MRI scans and health data from thousands of women worldwide to track changes in brain structure and connectivity.
A clinical trial led by Columbia University researchers found that valacyclovir, a common antiviral for herpes simplex infections, does not change the course of early Alzheimer's disease. Patients treated with valacyclovir showed no significant improvement in memory functions or brain structure compared to those receiving a placebo.
A study from Gladstone Institutes reveals that genetic risk factors for neurological diseases like Alzheimer’s and stroke exert their effects in blood vessels and immune cells. The research provides a detailed look at how genetic variants function across all major brain cell types, revealing distinct mechanisms for different diseases.
The US POINTER trial found that a structured lifestyle intervention of regular exercise, adherence to the MIND diet and social engagement had greater benefits on global cognition compared to an unstructured intervention. The study showed significant cognitive benefit after two years in older adults at elevated risk of Alzheimer disease.
UCSF scientists identified a receptor that enables microglia to engulf and digest amyloid beta plaques, leading to fewer and smaller clumps. This discovery creates an opportunity for new therapies targeting the receptor ADGRG1.
A recent study published in Brain reveals that a mathematical model can classify genes into four categories based on their interaction with the brain's network patterns. This classification helps explain why some brain regions deteriorate rapidly while others remain intact, providing new insights into Alzheimer's disease.
A groundbreaking brain imaging study confirms intranasal insulin safely reaches key memory regions in older adults with Alzheimer's. The research reveals differences in uptake among individuals with early cognitive decline, paving the way for personalized treatment approaches.
Aging and depression are linked to complex brain-body communication, with organs aging at different rates and influencing disease susceptibility. Dr. Hamilton Oh's research reveals how immune cells and metabolic organs amplify or dampen mood symptoms, offering novel therapeutic targets.
Researchers discovered a two-step mechanism where inhibitory neurons release nitric oxide to rapidly dilate blood vessels, followed by slower, localized vasodilation via astrocyte activation. This breakthrough sheds light on how neural signals are translated into blood volume changes in brain imaging.
A combination of two approved cancer medications may slow or reverse Alzheimer's symptoms by reversing gene expression changes in neurons and brain cells. Researchers analyzed public data from deceased donors and found a link between these drugs and reduced risk of developing the disease.
A new study from Emory University reveals that maintaining optimal cardiovascular health can significantly improve overall physical and psychological well-being. The review confirms that heart-healthy behaviors positively impact brain function, vision, hearing, muscle strength, and reduce the risk of chronic diseases.
Researchers used an AI model to reassess a completed clinical trial for an Alzheimer's disease drug, finding it slowed cognitive decline by 46% in early-stage patients. The AI model predicts patient progression and allows for more precise selection of trial participants, potentially reducing the cost of developing new medicines.
Research reveals insulin resistance and dysglycemia contribute to Alzheimer's disease progression, affecting cognitive function. The study identifies new gold standards for clinical care practice, including metformin and other glucose-lowering agents.
Scientists have discovered that microglia play a crucial role in regulating blood flow to the brain, and targeting them may improve blood flow deficits. The study suggests that restoring microglia function could prevent or reverse memory-stealing diseases caused by lack of adequate blood flow.
Researchers at the University of New Mexico are launching a Phase 1a/1b clinical trial for a new vaccine engineered to clear pathological tau protein from the brains of patients with Alzheimer’s dementia. The trial aims to assess the safety and immunogenicity of the novel vaccine.
A Finnish population study reveals that middle-aged individuals can have high levels of blood-based biomarkers associated with Alzheimer's disease. The study found a link between kidney disease and higher biomarker levels in middle age, as well as an association between the APOE ε4 gene and older age biomarker concentrations. Further r...
The UK Biobank has completed a groundbreaking imaging project, scanning the brains, hearts, abdomens, blood vessels, bones and joints of 100,000 volunteers to understand how diseases develop. The project is already improving patient care in the NHS and beyond, with over 1,300 peer-reviewed scientific papers published based on the data.
A Johns Hopkins study identifies over 200 types of misfolded proteins associated with age-related cognitive decline in rats. The findings suggest that these proteins may contribute to Alzheimer's and dementia beyond just the previously known A-beta and tau amyloids.
Researchers discovered that ApoE3 Christchurch interacts with tau and supports Wnt signaling, two key mechanisms that help prevent Alzheimer's-related damage. This finding opens the door to new treatment strategies, including therapies inspired by the variant's protective effects.
A novel AI-based approach identifies a distinct physicochemical signature near the cleavage site of gamma-secretase substrates, revealing dynamic properties essential for molecular recognition. The study highlights the potential of this methodology to improve understanding of gamma-secretase's role in diseases and aid drug development.
A new study reveals that Alzheimer's risk genes influence tau buildup and spread in distinct pathways, challenging traditional views of the disease. Four gene types were identified: Network-Aligned Vulnerability and Resilience, and Network-Independent Vulnerability and Resilience.
The study identified a rare genetic alteration associated with high levels of the ADAM10 protein, which plays a role in breaking down beta-amyloid precursor protein. The researchers aim to develop a panel of prognostic biomarkers to differentiate Alzheimer's disease from other types of dementia.
A recent study using machine learning and computational modeling reveals that astrocytes play a more active role in brain function than previously thought. Astrocytes subtly modulate communication between neurons during synchronous brain activity, influencing network coordination and stability.
Researchers identified four distinct pathways leading to Alzheimer's disease, revealing how conditions progress step-by-step toward the condition. The study validated findings in a nationally diverse population, suggesting that understanding these pathways could fundamentally change how clinicians approach early detection and prevention.
A new blood biomarker, p-tau217, has been identified as a potential predictor of Alzheimer's disease progression. This marker shows promise in identifying individuals at higher risk of developing the disease, allowing for early intervention and targeted treatment.
Non-invasive vagus nerve stimulation (nVNS) has demonstrated efficacy in reducing seizure frequency, improving mood, and enhancing motor recovery in various conditions. Future research should prioritize standardized protocols, large-scale trials, and biomarker development to personalize treatment.
The brain segments and organizes events into experiences by placing unique bookmarks on them, allowing us to revisit and learn from our lives. The lateral entorhinal cortex creates a signal that constantly drifts in a pattern never repeating itself, marking the beginning and end of an experience.
A recent study suggests that stressful life events can impact brain health differently depending on gender and educational level. The death of a partner was associated with changes in biomarkers related to Alzheimer's disease, while unemployment and economic losses were linked to structural differences in the brain.
Researchers have generated a first large-scale stem cell bank from over 100 individuals with extreme Alzheimer's disease risk. This new resource, called iPSC Platform to Model Alzheimer’s disease Risk (IPMAR), will facilitate studies on the impact of genetic variants in cellular models of AD.
Researchers at Baylor College of Medicine discovered that specific blood stem cell mutations may lower the risk for developing late-onset Alzheimer's disease. The study proposed a mechanism to protect against the disease and opens new avenues for potential strategies to control its emergence and progression.
A new study found that amylin administration exacerbates tauopathy by impairing lysosomal mechanisms in a hybrid diabetes model. The research highlights the intricate relationship between diabetes and Alzheimer's disease, suggesting that amylin plays a key role in the pancreas-brain axis.
A new study from the Buck Institute has uncovered how breaking down glycogen in neurons may protect against toxic protein buildup and degeneration. Researchers found that restoring an enzyme called glycogen phosphorylase can reduce tau-related damage and improve oxidative stress reduction.
Researchers found that low-intensity rTMS can increase synaptic plasticity of cortical axons in mouse models of Alzheimer's disease, particularly in excitatory boutons. This suggests potential as a targeted treatment to improve quality of life for AD patients.
Researchers at UCLA Health have made a groundbreaking discovery about the mechanisms underlying vascular dementia. They found that targeting inflammation in brain blood vessels can promote brain repair and functional recovery in mice. This breakthrough highlights a potential new treatment approach for this understudied form of dementia.
The AI tool, StateViewer, helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single scan. It enables clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows.
The new centre will investigate neural dynamics, developing novel interventions and devices to improve symptom relief and quality of life for people with brain disorders. It aims to harness neural dynamics for people with conditions like Parkinson’s disease or epilepsy.
Lars Lannfelt's pioneering research on Alzheimer's disease led to the development of lecanemab, a first-ever disease-modifying drug in EU. The €60,000 Hartwig Piepenbrock-DZNE Prize honors his contributions to understanding Alzheimer's and slowing its progression.